Limitations	NNS	O
to	IN	O
the	DT	O
widespread	JJ	O
use	NN	O
of	IN	O
PET	NNP	O
arise	VBP	O
from	IN	O
the	DT	O
high	JJ	O
costs	NNS	O
of	IN	O
cyclotrons	NNS	O
needed	VBN	O
to	TO	O
produce	VB	O
the	DT	O
short	JJ	O
-	HYPH	O
lived	VBN	O
radionuclides	NNS	O
for	IN	O
PET	NNP	O
scanning	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
specially	RB	O
adapted	VBN	O
on	IN	O
-	HYPH	O
site	NN	O
chemical	NN	O
synthesis	NN	O
apparatus	NN	O
to	TO	O
produce	VB	O
the	DT	O
radiopharmaceuticals	NNS	O
.	.	O
Few	JJ	B
hospitals	NNS	I
and	CC	I
universities	NNS	I
are	VBP	O
capable	JJ	O
of	IN	O
maintaining	VBG	O
such	JJ	O
systems	NNS	O
,	,	O
and	CC	O
most	JJS	B
clinical	JJ	I
PET	NN	I
is	VBZ	O
supported	VBN	O
by	IN	O
third	JJ	O
-	HYPH	O
party	NN	O
suppliers	NNS	O
of	IN	O
radiotracers	NNS	O
which	WDT	O
can	MD	O
supply	VB	O
many	JJ	B
sites	NNS	I
simultaneously	RB	O
.	.	O
This	DT	O
limitation	NN	O
restricts	VBZ	O
clinical	JJ	O
PET	NNP	O
primarily	RB	O
to	IN	O
the	DT	O
use	NN	O
of	IN	O
tracers	NNS	O
labelled	VBN	O
with	IN	O
F-18	NNP	O
,	,	O
which	WDT	O
has	VBZ	O
a	DT	O
half	JJ	O
life	NN	O
of	IN	O
110	CD	O
minutes	NNS	O
and	CC	O
can	MD	O
be	VB	O
transported	VBN	O
a	DT	O
reasonable	JJ	O
distance	NN	O
before	IN	O
use	NN	O
,	,	O
or	CC	O
to	IN	O
rubidium-82	NNP	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
created	VBN	O
in	IN	O
a	DT	O
portable	JJ	O
generator	NN	O
and	CC	O
is	VBZ	O
used	VBN	O
for	IN	O
myocardial	JJ	O
perfusion	NN	O
studies	NNS	O
.	.	O
Nevertheless	RB	O
,	,	O
in	IN	O
recent	JJ	O
years	NNS	O
a	DT	O
few	JJ	O
on	IN	O
-	HYPH	O
site	NN	O
cyclotrons	NNS	O
with	IN	O
integrated	VBN	O
shielding	VBG	O
and	CC	O
hot	JJ	O
labs	NNS	O
have	VBP	O
begun	VBN	O
to	TO	O
accompany	VB	O
PET	NNP	O
units	NNS	O
to	IN	O
remote	JJ	O
hospitals	NNS	O
.	.	O
